Home » Whitepaper – Precision medicine for non-small cell lung cancer (NSCLC)

Whitepaper – Precision medicine for non-small cell lung cancer (NSCLC)

Created: October 22, 2025

Lung cancer remains the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) accounting for the majority of cases—and the need for better targeted therapies has never been greater. The NSCLC 2025 whitepaper offers an in-depth view into the latest trends in molecular analysis and precision medicine for NSCLC, revealing how new technologies like immunohistochemistry (IHC), next-generation sequencing (NGS), and liquid biopsy (ctDNA) are transforming therapeutic development and patient outcomes.

What You'll Learn?

How NCCN guidelines are driving broad molecular profiling for more personalized treatment regimens

The advantages of multiplex IHC panels and the array of actionable biomarkers now detectable in a single test

The vital role of NGS and ctDNA in identifying driver mutations, guiding therapies, and minimizing invasive procedures

HBRI’s global expertise, technologies aligned with NCCN guidelines, and biobank resources are accelerating NSCLC clinical trials

"*" indicates required fields